Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors in Phase III NSCLC Trial
Genentech Reports Positive Phase III Krascendo 1 Results Demonstrating Divarasib Improves Survival in Previously Treated KRAS G12C Non-Small Cell Lung Cancer Genentech, a member of the Roche Group, has announced…
VIVAZEN® Welcomes DEA Scheduling of Synthetic 7-Hydroxymitragynine
VIVAZEN Welcomes DEA Scheduling of Synthetic 7-Hydroxymitragynine, Reinforces Commitment to Safe Botanical Wellness and Consumer Transparency VIVAZEN®, a leading botanical wellness company in the United States, has welcomed the recent…
Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer
Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Drive Global Growth and Strengthen Biologics CDMO Capabilities Rezon Bio, a science-driven European contract development and manufacturing organization (CDMO)…
Caidya and Simbec-Orion Announce Strategic Combination
Caidya and Simbec-Orion Combine to Create Global Specialty CRO Platform Spanning Early-Phase Research Through Late-Stage Clinical Development Caidya has announced a strategic combination with Simbec-Orion, marking a significant step in…
Azalea Vision Secures EIC Accelerator Funding for Smart Contact Lens
Azalea Vision Secures Up to €7.5 Million from European Innovation Council to Advance Smart Contact Lens Platform Toward Clinical Development Belgian health technology innovator Azalea Vision has secured a major…
SC Therapeutics Initiates REACH2 Clinical Trial in Refractory Chronic Cough
SC Therapeutics Launches REACH2 Clinical Trial to Evaluate Novel Disease-Modifying Therapy for Refractory Chronic Cough SC Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies that target mechano-sensitive ion…
HeartBeam Completes Enrollment for Heart Attack Detection Pilot Study
HeartBeam Completes Patient Enrollment Ahead of Schedule in ALIGN-ACS Pilot Study for Heart Attack Detection HeartBeam, Inc., a medical technology company focused on advancing cardiovascular diagnostics through innovative electrocardiogram (ECG)…
Colossal Foundation Partners with University of Tasmania to Combat Devil Facial Tumour Disease
Colossal Foundation and University of Tasmania Launch Multi-Pronged Initiative to Combat Deadly Tasmanian Devil Facial Tumour Disease The Colossal Foundation, the nonprofit conservation organization established by Colossal Biosciences, has announced…
FNIH Launches Music as Medicine Neuroscience Initiative
FNIH and Leading Advocates Launch Music as Medicine Neuroscience Initiative The Foundation for the National Institutes of Health (FNIH) has announced the launch of the Music as Medicine Neuroscience Research…
CorVista Health Receives AMA Category III CPT® Code for AI Cardiopulmonary Analysis
CorVista Health Receives New AMA Category III CPT Code for AI-Powered Cardiovascular Diagnostic Technology CorVista Health has announced that the American Medical Association (AMA) has approved a new Category III…
Croma-Pharma Wins FDA Approval for Obagi saypha® ChIQ™ in the U.S.
Croma-Pharma Secures FDA Approval for Obagi saypha® ChIQ™ to Expand Facial Aesthetic Treatment Options in the U.S. Croma-Pharma has reached another significant milestone in its global growth strategy with the…
Hengrui’s Heng Yi® Approved in China for Dry Eye Disease Treatment
Hengrui’s Heng Yi® Approved in China for Dry Eye Disease Treatment Hengrui Pharma and Novaliq GmbH have announced that China’s National Medical Products Administration (NMPA) has approved Heng Yi® (0.1%…